Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date

Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date

Jordi Remon,1 Laura Esteller,1 Álvaro Taus2,31Centro Integral Oncología Clara Campal Barcelona, HM-Delfos, Medical Oncology Department, Barcelona, Spain; 2Hospital del Mar, Medical Oncology Department, Barcelona, Spain; 3Oncology Department, Cancer Research Program, IMIM (Hospi...

Full description

Bibliographic Details
Main Authors: Remon J, Esteller L, Taus Á
Format: Article
Language:English
Published: Dove Medical Press 2019-05-01
Series:Cancer Management and Research
Subjects:
nivolumab and ipilimumab
tumor mutational burden
CheckMate trial
non-small cell lung cancer
Online Access:https://www.dovepress.com/nivolumab-plus-ipilimumab-combination-therapy-for-the-first-line-treat-peer-reviewed-article-CMAR

Internet

https://www.dovepress.com/nivolumab-plus-ipilimumab-combination-therapy-for-the-first-line-treat-peer-reviewed-article-CMAR

Similar Items